6-Thio-2'-Deoxyguanosine

Phase 3

MAIA Biotechnology, Inc. (MAIA)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

MAIAPhase 2$82M

6-Thio-2'-Deoxyguanosine Phase 2 Est. Readout

6-Thio-2'-Deoxyguanosine• Carcinoma, Non-Small-Cell Lung227

Q3 2027~QEstimated

CT.gov

00%

Q3 '27

MAIAPhase 3$82M

6-Thio-2'-Deoxyguanosine Phase 3 Est. Readout

6-Thio-2'-Deoxyguanosine• Carcinoma, Non-Small-Cell Lung300

Q3 2027~QEstimated

CT.gov

00%

Competitive Landscape

7 competitors in Carcinoma, Non-Small-Cell Lung

LLYIMC-1121B (ramucirumab)

Phase 2

CASIrecombinant human Angiostatin protein

Drug Information

Target Indication

Carcinoma, Non-Small-Cell Lung

Clinical Trial

NCT05208944

Last updated: 1/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

MAIA

MAIA Biotechnology, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

VinorelbinePhase 3

Carcinoma, Non-Small -Cell Lung

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts